| Theme | Guideline for CKD-related anemia -- looking back twice's revision | |
|---|---|---|
| Title | Advantages and disadvantages of ferrotherapy via oral and intravenous route of administration for patients with CKD | |
| Publish Date | 2017/02 | |
| Author | Kimio Watanabe | Division of Blood Purification, Tohoku University Hospital |
| Author | Masaaki Nakayama | Research Division of Chronic Kidney Disease and Dialysis treatment, Tohoku University Hospital |
| [ Summary ] | In Japan, the administration of oral and intravenous iron is approved for patients with non-dialysis chronic kidney disease (CKD) and those with CKD undergoing hemodialysis or peritoneal dialysis. Increased risk of infection, adverse cardiovascular events, and the upregulation of oxidative stress are of particular concern in ferrotherapy, and these effects are considered to vary depending on the route of administration. Several recent reports indicated that an iron-based phosphate binder (ferric citrate) improves anemia in patients with CKD. Additionally, the efficacy of oral iron administration has been receiving more attention. In this section, we expound upon the advantages and disadvantages of ferrotherapy via each route of administration. | |